Baseline characteristics

Related by string. * baselines . Baselines . BASELINES . BASELINE . baseline : Baseline Scenario . sank baseline jumper . Baseline Killer . baseline jumper . baseline floater / CHARACTERISTICS . Characteristics . Characteristic : Market Characteristics chapter . demographic characteristics . distinguishing characteristics . distinguishing characteristic . defining characteristic * *

Related by context. Frequent words. (Click for all words.) 68 laboratory abnormalities 66 nondiabetic 64 Median survival 63 HbA 1c 63 HbA1c levels 63 multivariate analyzes 63 Adverse events 62 coinfected 62 confidence interval CI 62 fasting insulin 62 ± SD 62 virologic response 62 estimated glomerular filtration 62 LVEF 62 serum concentrations 61 Secondary endpoints 61 MetS 61 mg kg dose 61 active comparator 60 prognostic factors 60 achieved statistical significance 60 % CI #.#-#.# [007] 60 fasting glucose levels 60 liver transplant recipients 60 virologic failure 60 sd = 60 sociodemographic 60 P = .# 60 serum calcium 60 comorbid conditions 60 dose regimens 59 discontinuations due 59 events SAEs 59 univariate 59 secondary efficacy endpoints 59 heavily pretreated 59 CI -#.# 59 plus methotrexate 59 % CI #.#-#.# [006] 59 prespecified 59 pg ml 59 statistically significant differences 59 chlorambucil 59 mg BID 59 preoperatively 59 confidence interval #.#-#.# 59 systemic embolism 58 events AEs 58 hypoglycemic events 58 severe renal impairment 58 irbesartan 58 subgroup analyzes 58 KRAS mutations 58 DAS# [002] 58 antihypertensive medications 58 HRQoL 58 univariate analysis 58 histologically 58 covariates 58 treatment emergent adverse 58 glomerular filtration rate 58 XELOX 58 potential confounders 58 vertebral fracture 58 glycated hemoglobin 58 placebo controlled clinical trials 58 HRQOL 57 comorbidities 57 eGFR 57 creatinine clearance 57 serum uric acid 57 pg mL 57 lipid lowering therapy 57 n = 57 statistically significant p = 57 NYHA class 57 mineral density 57 evaluable 57 quartiles 57 leukopenia 57 ADAS cog 57 glimepiride 57 hyperbilirubinemia 57 placebo controlled trials 57 lipid profiles 57 myocardial infarctions 57 TAXUS Stent 57 mg QD 57 cytogenetic response 56 cerebrovascular events 56 serum phosphorus 56 g dL 56 PsA 56 lymph node involvement 56 ALLHAT 56 peginterferon alfa 2b 56 unfractionated heparin 56 kg/m2 56 confounding variables 56 nonsignificant 56 dose cohorts

Back to home page